Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil and melatonin added to metformin in polycystic ovary syndrome
IRCT20230427058010N1Phase 3Completed
- Sponsor
- Imam Sajjad Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sildenafil, melatonin and metformin in polycystic ovary syndrome (PCOS) (4 arms), sponsored by Imam Sajjad Hospital. Primary endpoints: Malondialdehyde, Nitric oxide metabolites and 4 more. Started Mar 2024; status: completed.
02
Drugs
sildenafilmelatoninmetformin
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on IRCT20230427058010N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230427058010N1.